Lukas C. Amler
PCR Oncology(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics, Monoclonal and Polyclonal Antibodies Research, Melanoma and MAPK Pathways
Most-Cited Works
- → Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib(2005)1,482 cited
- → Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab(2018)1,185 cited
- → Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts(2005)832 cited
- → Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy(2010)758 cited
- → Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL(2007)602 cited
- → Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients(2005)490 cited
- → Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer(2006)481 cited
- → In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models(2009)472 cited
- → Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib(2012)417 cited
- → A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine(2012)362 cited